李梦玮，中国药科大学生命科学与技术学院副研究员，硕士研究生导师。长期聚焦利用多组学技术联合分析、生物信息学、基因编辑等手段建立全新微肽的发现平台，揭示肿瘤网络调控和诊疗新靶标分子。近年来以一作/共一作在Mol. Cancer、J. Am. Chem. Soc.、Signal Transduct Target Ther、Cancer Lett、Acta Pharm Sin B、Cell Death Dis等杂志发表多篇高水平SCI文章，其中影响因子10分以上的5篇，并申请发明专利四项，授权两项。目前主持国家自然科学基金、国家重点研发计划（一级子课题负责人）、江苏省自然科学基金等项目，并担任中国药科大学学报、JCTR期刊青年编委，Cancer Advances期刊审稿人。热忱欢迎对课题组感兴趣的本科生和研究生加入实验室。
| 非编码RNA来源的全新微肽发现和功能机制研究 |
(1) Mengwei Li#, Guangxiang Liu#, Hanmei Xu*, et al. Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma. Mol Cancer. 2022, 21(1): 181. (IF 37.3)
(2) Mengwei Li#, Chi, Xiaowei, Xu, Hanmei*, et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy. 2022, 7: 1-25. (IF 39.3)
(3) Setrerrahmane S#, Mengwei Li#, Hanmei Xu*, et al. Cancer-related micropeptides encoded by ncRNAs: Promising drug targets and prognostic biomarkers. Cancer Lett. 2022: 215723. (IF 9.7)
(4) Ying Wang#, Mengwei Li#, Lin Chen, Hanmei Xu*, et al. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes. Signal Transduction and Targeted Therapy. 2021, 6: 1-13. (IF 38.1)
(5) Meng Li#, Ying Wang#, Mengwei Li#, Hanmei Xu*, et al. Integrins as attractive targets for cancer therapeutics. Acta Pharmaceutica Sinica B. 2021, 11: 2726-2737. (IF 14.9)
(6) Mengwei Li#; Xin Li#; Yinan Zhang; Hanmei Xu*, et al. Micropeptide MIAC Inhibits HNSCC Progression by Interacting with Aquaporin 2. Journal of the American Chemical Society. 2020, 142: 6708-6716. (IF 15.4)
(7) Mengwei Li#, Xu Ding#, Yinan Zhang, Hanmei Xu*, et al. Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas. Cell Death & Disease. 2020, 11: 1-12. (IF 8.5)
